vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and LXP Industrial Trust (LXP). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $86.7M, roughly 1.9× LXP Industrial Trust). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -14.0%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 0.3%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
LXP Industrial Trust is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality industrial real estate assets, primarily distribution centers, logistics facilities, and light industrial properties across key markets in the United States. Its tenant base covers e-commerce, third-party logistics, and advanced manufacturing sectors, delivering stable long-term returns for its investors.
ESPR vs LXP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $86.7M |
| Net Profit | — | $28.8M |
| Gross Margin | — | 81.5% |
| Operating Margin | 50.6% | 34.6% |
| Net Margin | — | 33.2% |
| Revenue YoY | 143.7% | -14.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $86.7M | ||
| Q3 25 | $87.3M | $86.9M | ||
| Q2 25 | $82.4M | $87.7M | ||
| Q1 25 | $65.0M | $88.9M | ||
| Q4 24 | $69.1M | $100.9M | ||
| Q3 24 | $51.6M | $85.6M | ||
| Q2 24 | $73.8M | $85.8M | ||
| Q1 24 | $137.7M | $86.3M |
| Q4 25 | — | $28.8M | ||
| Q3 25 | $-31.3M | $36.3M | ||
| Q2 25 | $-12.7M | $29.1M | ||
| Q1 25 | $-40.5M | $19.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $6.3M | ||
| Q2 24 | $-61.9M | $5.4M | ||
| Q1 24 | $61.0M | $-269.0K |
| Q4 25 | — | 81.5% | ||
| Q3 25 | — | 82.3% | ||
| Q2 25 | — | 81.9% | ||
| Q1 25 | — | 80.7% | ||
| Q4 24 | — | 85.3% | ||
| Q3 24 | — | 82.5% | ||
| Q2 24 | — | 82.0% | ||
| Q1 24 | — | 82.4% |
| Q4 25 | 50.6% | 34.6% | ||
| Q3 25 | -11.4% | 50.4% | ||
| Q2 25 | 8.6% | 33.7% | ||
| Q1 25 | -34.0% | 21.8% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | 7.9% | ||
| Q2 24 | 3.5% | 6.9% | ||
| Q1 24 | 52.5% | 1.0% |
| Q4 25 | — | 33.2% | ||
| Q3 25 | -35.9% | 41.7% | ||
| Q2 25 | -15.4% | 33.2% | ||
| Q1 25 | -62.2% | 21.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | 7.4% | ||
| Q2 24 | -83.9% | 6.3% | ||
| Q1 24 | 44.3% | -0.3% |
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | $0.12 | ||
| Q2 25 | $-0.06 | $0.09 | ||
| Q1 25 | $-0.21 | $0.06 | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.15 | $0.02 | ||
| Q2 24 | $-0.33 | $0.01 | ||
| Q1 24 | $0.34 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $170.4M |
| Total DebtLower is stronger | — | $1.4B |
| Stockholders' EquityBook value | $-302.0M | $2.0B |
| Total Assets | $465.9M | $3.5B |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $170.4M | ||
| Q3 25 | $92.4M | $229.7M | ||
| Q2 25 | $86.1M | $71.0M | ||
| Q1 25 | $114.6M | $70.9M | ||
| Q4 24 | $144.8M | $101.8M | ||
| Q3 24 | $144.7M | $55.0M | ||
| Q2 24 | $189.3M | $48.7M | ||
| Q1 24 | $226.6M | $293.8M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-302.0M | $2.0B | ||
| Q3 25 | $-451.4M | $2.1B | ||
| Q2 25 | $-433.5M | $2.1B | ||
| Q1 25 | $-426.2M | $2.1B | ||
| Q4 24 | $-388.7M | $2.1B | ||
| Q3 24 | $-370.2M | $2.1B | ||
| Q2 24 | $-344.2M | $2.1B | ||
| Q1 24 | $-294.3M | $2.2B |
| Q4 25 | $465.9M | $3.5B | ||
| Q3 25 | $364.0M | $3.7B | ||
| Q2 25 | $347.1M | $3.7B | ||
| Q1 25 | $324.0M | $3.8B | ||
| Q4 24 | $343.8M | $3.8B | ||
| Q3 24 | $314.1M | $3.9B | ||
| Q2 24 | $352.3M | $3.9B | ||
| Q1 24 | $373.1M | $4.2B |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.72× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $188.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 6.56× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $188.7M | ||
| Q3 25 | $-4.3M | $63.5M | ||
| Q2 25 | $-31.4M | $44.3M | ||
| Q1 25 | $-22.6M | $39.0M | ||
| Q4 24 | $-35.0M | $211.2M | ||
| Q3 24 | $-35.3M | $64.6M | ||
| Q2 24 | $-7.2M | $38.5M | ||
| Q1 24 | $53.8M | $38.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — | ||
| Q1 24 | 39.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 6.56× | ||
| Q3 25 | — | 1.75× | ||
| Q2 25 | — | 1.52× | ||
| Q1 25 | — | 2.05× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.18× | ||
| Q2 24 | — | 7.09× | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
LXP
Segment breakdown not available.
